At the highest viral dose examined, H5CmTERT-Ad/TRAIL elicited a 4.2- or 2.0-fold stronger cancer cell-killing effect than H5CmTERT-Ad did in glioblastoma cells (U87MG and U251N, respectively) during normoxia. The gene discussed is TNFSF10; the disease is glioblastoma.